CN108853144A - Toll样受体激动剂与免疫效应细胞的联用 - Google Patents

Toll样受体激动剂与免疫效应细胞的联用 Download PDF

Info

Publication number
CN108853144A
CN108853144A CN201810469904.7A CN201810469904A CN108853144A CN 108853144 A CN108853144 A CN 108853144A CN 201810469904 A CN201810469904 A CN 201810469904A CN 108853144 A CN108853144 A CN 108853144A
Authority
CN
China
Prior art keywords
cell
antigen
receptor
immune effector
effector cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810469904.7A
Other languages
English (en)
Chinese (zh)
Inventor
李宗海
狄升蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clegg Medical Co ltd
Original Assignee
Keji Biomedical (shanghai) Co Ltd
Shanghai Cancer Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keji Biomedical (shanghai) Co Ltd, Shanghai Cancer Institute filed Critical Keji Biomedical (shanghai) Co Ltd
Publication of CN108853144A publication Critical patent/CN108853144A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464404—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201810469904.7A 2017-05-16 2018-05-16 Toll样受体激动剂与免疫效应细胞的联用 Pending CN108853144A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2017103445585 2017-05-16
CN201710344558 2017-05-16
CN201710561825 2017-07-11
CN2017105618254 2017-07-11

Publications (1)

Publication Number Publication Date
CN108853144A true CN108853144A (zh) 2018-11-23

Family

ID=64273505

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810469904.7A Pending CN108853144A (zh) 2017-05-16 2018-05-16 Toll样受体激动剂与免疫效应细胞的联用

Country Status (2)

Country Link
CN (1) CN108853144A (fr)
WO (1) WO2018210279A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020143631A1 (fr) * 2019-01-07 2020-07-16 科济生物医药（上海）有限公司 Association pour immunothérapie cellulaire
CN111434692A (zh) * 2019-01-15 2020-07-21 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN111875708A (zh) * 2020-05-28 2020-11-03 浙江康佰裕生物科技有限公司 一种嵌合抗原受体t淋巴细胞及其在制备治疗实体肿瘤的产品中的应用
CN113501885A (zh) * 2021-07-20 2021-10-15 中国农业大学 嵌合抗病基因及其相关生物材料与应用
WO2022017429A1 (fr) * 2020-07-24 2022-01-27 沣潮医药科技（上海）有限公司 Récepteur antigénique chimérique pour clairance de pathogènes et utilisation associée
WO2022028623A1 (fr) 2020-08-07 2022-02-10 佧珐药业有限公司 Cellules modifiées et procédé de modification de cellules
CN114729028A (zh) * 2019-08-29 2022-07-08 克莱格医学有限公司 抗移植反应的细胞和方法
WO2022214089A1 (fr) 2021-04-08 2022-10-13 克莱格医学有限公司 Utilisation d'immunothérapie cellulaire
WO2023274303A1 (fr) 2021-06-29 2023-01-05 科济生物医药（上海）有限公司 Polypeptide chimérique pour la régulation de l'activité physiologique cellulaire

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220528A1 (en) * 2005-06-17 2009-09-03 The Trustees Of The Univeristy Of Pennsylvania Cneter For Technology Transfer Stimulation of Toll-Like Receptors on T Cells
CN101990435A (zh) * 2008-02-15 2011-03-23 海米斯费克斯生物制药公司 Toll样受体3的选择性激动剂
CN104136614A (zh) * 2009-10-06 2014-11-05 帕纳塞拉实验室股份有限公司 Toll-样受体和激动剂用于治疗癌症的用途
WO2015165997A1 (fr) * 2014-04-29 2015-11-05 Medizinische Hochschule Hannover Vaccin
CN105228450A (zh) * 2013-05-18 2016-01-06 艾杜罗生物科技公司 用于活化“干扰素基因刺激因子”-依赖性信号传导的组合物和方法
CN105431524A (zh) * 2013-06-10 2016-03-23 达娜-法勃肿瘤研究所公司 用于降低通过肿瘤细胞的免疫抑制的方法和组合物
CN105452287A (zh) * 2013-04-17 2016-03-30 贝勒医学院 免疫抑制性TGF-β信号转换器
WO2016177833A1 (fr) * 2015-05-04 2016-11-10 Bionor Immuno As Schéma posologique pour un vaccin contre le vih
CN106163547A (zh) * 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症
US20170014452A1 (en) * 2015-07-16 2017-01-19 Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center Compositions and methods for treating peritoneal cancers
CN106397593A (zh) * 2015-08-03 2017-02-15 科济生物医药（上海）有限公司 抗磷脂酰肌醇蛋白多糖‑3的抗体及其应用
CN106456724A (zh) * 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220528A1 (en) * 2005-06-17 2009-09-03 The Trustees Of The Univeristy Of Pennsylvania Cneter For Technology Transfer Stimulation of Toll-Like Receptors on T Cells
CN101990435A (zh) * 2008-02-15 2011-03-23 海米斯费克斯生物制药公司 Toll样受体3的选择性激动剂
CN104136614A (zh) * 2009-10-06 2014-11-05 帕纳塞拉实验室股份有限公司 Toll-样受体和激动剂用于治疗癌症的用途
CN105452287A (zh) * 2013-04-17 2016-03-30 贝勒医学院 免疫抑制性TGF-β信号转换器
CN105228450A (zh) * 2013-05-18 2016-01-06 艾杜罗生物科技公司 用于活化“干扰素基因刺激因子”-依赖性信号传导的组合物和方法
CN105431524A (zh) * 2013-06-10 2016-03-23 达娜-法勃肿瘤研究所公司 用于降低通过肿瘤细胞的免疫抑制的方法和组合物
CN106456724A (zh) * 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
CN106163547A (zh) * 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症
WO2015165997A1 (fr) * 2014-04-29 2015-11-05 Medizinische Hochschule Hannover Vaccin
WO2016177833A1 (fr) * 2015-05-04 2016-11-10 Bionor Immuno As Schéma posologique pour un vaccin contre le vih
US20170014452A1 (en) * 2015-07-16 2017-01-19 Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center Compositions and methods for treating peritoneal cancers
TW201716072A (zh) * 2015-07-16 2017-05-16 展望憑照看護公司亦以羅傑威廉斯醫療中心名稱營業 治療腹膜癌之組成物和方法
CN106397593A (zh) * 2015-08-03 2017-02-15 科济生物医药（上海）有限公司 抗磷脂酰肌醇蛋白多糖‑3的抗体及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LAI Y等3: "Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells", 《LEUKEMIA》 *
SELEDTSOV VI等: "Clinically feasible approaches to potentiating cancer cell-based immunotherapies", 《HUM VACCIN IMMUNOTHER》 *
赵晓斌: "肿瘤疫苗的研究进展", 《现代免疫学》 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113271953A (zh) * 2019-01-07 2021-08-17 科济生物医药（上海）有限公司 细胞免疫治疗的组合
JP2022524906A (ja) * 2019-01-07 2022-05-11 クレージュ メディカル カンパニー，リミテッド 細胞免疫療法の組み合わせ
WO2020143631A1 (fr) * 2019-01-07 2020-07-16 科济生物医药（上海）有限公司 Association pour immunothérapie cellulaire
CN111434692B (zh) * 2019-01-15 2021-12-31 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN111434692A (zh) * 2019-01-15 2020-07-21 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN114729028A (zh) * 2019-08-29 2022-07-08 克莱格医学有限公司 抗移植反应的细胞和方法
CN111875708B (zh) * 2020-05-28 2021-05-04 浙江康佰裕生物科技有限公司 一种嵌合抗原受体t淋巴细胞及其在制备治疗实体肿瘤的产品中的应用
CN111875708A (zh) * 2020-05-28 2020-11-03 浙江康佰裕生物科技有限公司 一种嵌合抗原受体t淋巴细胞及其在制备治疗实体肿瘤的产品中的应用
WO2022017429A1 (fr) * 2020-07-24 2022-01-27 沣潮医药科技（上海）有限公司 Récepteur antigénique chimérique pour clairance de pathogènes et utilisation associée
WO2022028623A1 (fr) 2020-08-07 2022-02-10 佧珐药业有限公司 Cellules modifiées et procédé de modification de cellules
WO2022214089A1 (fr) 2021-04-08 2022-10-13 克莱格医学有限公司 Utilisation d'immunothérapie cellulaire
WO2023274303A1 (fr) 2021-06-29 2023-01-05 科济生物医药（上海）有限公司 Polypeptide chimérique pour la régulation de l'activité physiologique cellulaire
CN113501885A (zh) * 2021-07-20 2021-10-15 中国农业大学 嵌合抗病基因及其相关生物材料与应用
CN113501885B (zh) * 2021-07-20 2023-02-24 中国农业大学 嵌合抗病基因及其相关生物材料与应用

Also Published As

Publication number Publication date
WO2018210279A1 (fr) 2018-11-22

Similar Documents

Publication Publication Date Title
CN108853144A (zh) Toll样受体激动剂与免疫效应细胞的联用
JP7300763B2 (ja) Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
RU2685479C2 (ru) Химерный антигенный рецептор
JP6426713B2 (ja) Ｇｐｃ３キメラ抗原受容体蛋白質をコードする核酸及びｇｐｃ３キメラ抗原受容体蛋白質を発現するｔリンパ球
US11566223B2 (en) Chimeric antigen receptor cell preparation and uses thereof
CN108866003A (zh) 基因工程化的细胞及应用
CN110072885A (zh) TGFβ信号转换器
CN110267677A (zh) 使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
US11235004B2 (en) Lymphocyte cell lines and uses thereof
CN107106611A (zh) 用于提高过继细胞免疫疗法效力的组合物和方法
CN106535925A (zh) 基于car的免疫治疗
CN107964046A (zh) 对肿瘤细胞有特异性的嵌合抗原受体
CA3139346A1 (fr) Cellule immunitaire modifiee ciblant bcma et son utilisation
CN106999552A (zh) 治疗癌症的方法和组合物
Hemmi et al. Treml4, an Ig superfamily member, mediates presentation of several antigens to T cells in vivo, including protective immunity to HER2 protein
JP2022523749A (ja) Ｔｃｒ融合タンパク質およびｔｃｒ融合タンパク質を発現する細胞
TWI811278B (zh) 表現特異性辨識人類間皮素之細胞表面分子、il-7、及ccl19之免疫活性細胞
AU2019271819A1 (en) Genetically engineered cell and application thereof
JP2022500011A (ja) 固形腫瘍を治療するためのキメラ抗原受容体細胞
KR20230129979A (ko) 수지상 세포 활성화 키메라 항원 수용체 및 이의 용도
WO2021057906A1 (fr) Cellule effectrice immunitaire exprimant il-15
TW202026006A (zh) 使用融合蛋白進行tcr再程式化之組成物及方法
US20240082306A1 (en) Novel chimeric antigen receptor and use thereof
CN112771167A (zh) 表达有趋化因子的细胞及用途
CN110404061A (zh) 改进的t细胞治疗方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210908

Address after: Ai Erlandubailin

Applicant after: Fufa Pharmaceutical Co.,Ltd.

Address before: Building B, 388 Yindu Road, Xuhui District, Shanghai, 200231

Applicant before: Keji biomedical (Shanghai) Co.,Ltd.

Applicant before: SHANGHAI CANCER INSTITUTE

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220210

Address after: Room 12, 20th floor, Haojing commercial center, 2-16 Huayuan street, Mongkok, Kowloon, China

Applicant after: Clegg Medical Co.,Ltd.

Address before: Irish Dublin

Applicant before: Fufa Pharmaceutical Co.,Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20181123